Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV000488267 | SCV000574838 | benign | not provided | 2023-08-01 | criteria provided, single submitter | clinical testing | DNA2: BS1, BS2 |
Labcorp Genetics |
RCV000488267 | SCV001013656 | likely benign | not provided | 2023-12-30 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000488267 | SCV001797066 | likely benign | not provided | 2020-10-26 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004609403 | SCV005108397 | uncertain significance | Inborn genetic diseases | 2024-04-23 | criteria provided, single submitter | clinical testing | The c.1796G>A (p.R599H) alteration is located in exon 12 (coding exon 12) of the DNA2 gene. This alteration results from a G to A substitution at nucleotide position 1796, causing the arginine (R) at amino acid position 599 to be replaced by a histidine (H). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Mayo Clinic Laboratories, |
RCV000488267 | SCV000802295 | uncertain significance | not provided | 2016-02-22 | no assertion criteria provided | clinical testing | |
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV000488267 | SCV001959329 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000488267 | SCV001975922 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Prevention |
RCV003962350 | SCV004780158 | likely benign | DNA2-related disorder | 2021-10-14 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |